metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mHCC - (neo)adjuvant (NA) metastatic/advanced hepatocellular cancer (mHCC) mHCC - (neo)adjuvant (NA)
versus nivolumab alone
	nivolumab plus ipilimumab
	NCI-2018-01106, 2022 Lancet Gastroenterol Hepatol 2022; 7:208-218-. NCT03222076	RCT	hepatocell cancer (HCC)	nivolumab plus ipilimumab	nivolumab	Patients With Resectable and Potentially Resectable	14 / 13	NA	inconclusive	no statistically significant result
versus Standard of Care (SoC)
	atezolizumab plus bevacizumab
	IMbrave050, 2023 Lancet 2023; 402:1835-1847-. NCT04102098	RCT	mHCC - (neo)adjuvant (NA)	atezolizumab plus bevacizumab	active surveillance	adult patients with high-risk surgically resected or ablated hepatocellular carcinoma	334 / 334	NA	conclusif	demonstrated 28 % decrease in RFS/DFS (PE)
	sintilimab
	Wang, 2024 Nat Med 2024; 30:708-715-. ChiCTR2000037655	RCT	hepatocell cancer (HCC), mHCC - (neo)adjuvant (NA)	sintilimab	SOc		99 / 99	NA	conclusif	demonstrated 47 % decrease in RFS/DFS (PE) statistically significant 200.0-fold increase in AE (any grade) statistically significant 26.2-fold increase in AE (grade 3-4)